Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lung Neoplasms 6Sarcoma 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Colorectal Neoplasms 4Neoplasm Metastasis 3Colonic Neoplasms 3Thymoma 2Rectal Neoplasms 2Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma, Basal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Tobacco Use Disorder 1Temporomandibular Joint Disorders 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Smoking 1Small Cell Lung Carcinoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm, Residual 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Mesothelioma 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

Carboplatin 2tanespimycin 1sargramostim 1alethine 1Peripheral Blood Stem Cell Transplantation 1Interleukin-12 Subunit p35 1Interferon-alpha 1Imatinib Mesylate 1Ifosfamide 1Docetaxel 1Decitabine 1Cyclophosphamide 1Celecoxib 1Amifostine 1AH 111585 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Monoclonal Gammopathy of Undetermined Significance × Celecoxib × Clear all
NCT00099047 2016-12-30

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 7 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡